NRIX Nurix Therapeutics, Inc.
Healthcare$17.38-0.69%ClosedMarket Cap: $1.51B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.01
P/S
21.13
EV/EBITDA
-5.21
DCF Value
$-33.88
FCF Yield
-17.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-139.4%
Operating Margin
-439.3%
Net Margin
-411.4%
ROE
-64.2%
ROA
-46.4%
ROIC
-57.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $6.3M | -1245.8% | $-92.5M | $-87.2M | $— | — |
| Q4 null | $13.6M | 65.9% | $-83.1M | $-78.2M | $— | — |
| FY null | $84.0M | 77.5% | $-285.7M | $-264.5M | $— | — |
| Q3 null | $7.9M | 36.7% | $-91.4M | $-86.4M | $— | — |
| Q2 null | $44.1M | -77.3% | $-48.3M | $-43.5M | $— | — |
| Q1 null | $18.5M | -277.5% | $-62.9M | $-56.4M | $— | — |
| Q4 null | $13.3M | -406.1% | $-64.7M | $-58.5M | $— | — |
| FY null | $54.5M | -306.3% | $-213.0M | $-193.6M | $— | — |
| Q3 null | $12.6M | -340.7% | $-54.6M | $-49.0M | $— | — |
| Q2 null | $12.1M | -304.6% | $-48.5M | $-44.5M | $— | — |
| Q1 2024 | $16.6M | -201.5% | $-45.2M | $-41.5M | $-0.76 | — |
| Q4 2023 | $15.2M | -227.9% | $-45.3M | $-42.0M | $-0.77 | — |